Spyre Therapeutics Analyst Price Targets - Benzinga

Spyre Therapeutics Inc

SYRENASDAQ

Trade with Public

Trade with Public

$88.47

-0.03-0.03%

Últ. Act.: Sep 2, 9:54 AM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

Spyre Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Spyre Therapeutics (SYRE).

Price Target Range — 11 Quarters

Analyst Consensus — 15 Analysts

1S.Buy

14Buy

Consensus RatingBuy# Analysts15Avg. Consensus PT$99Upside to Avg. PT+11.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 26, 2026	Deutsche Bank	David Hoang	PT Cut	Buy	$135→$127
Aug 26, 2026	Wedbush	David Nierengarten	PT Cut	Outperform	$130→$123
Aug 26, 2026	BTIG	Julian Harrison	PT Cut	Buy	$132→$121
Aug 11, 2026	BTIG	Julian Harrison	PT Raise	Buy	$112→$132
Aug 5, 2026	Wells Fargo	Yanan Zhu	PT Raise	Overweight	$90→$115
Aug 5, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$115→$130
Aug 5, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$100→$130
Jul 28, 2026	Wolfe Research	Andy Chen	Downgrade	Outperform→Peer Perform	—
Jul 13, 2026	Mizuho	Joseph Catanzaro	PT Raise	Outperform	$84→$120
Jun 23, 2026	Deutsche Bank	David Hoang	PT Raise	Buy	$115→$135
Jun 15, 2026	BTIG	Julian Harrison	PT Raise	Buy	$98→$112
Jun 4, 2026	Deutsche Bank	David Hoang	PT Raise	Buy	$102→$115
May 6, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$64→$97
May 6, 2026	Stifel	Alex Thompson	PT Raise	Buy	$92→$107
Apr 17, 2026	Jones Trading	Debanjana Chatterjee	PT Raise	Buy	$64→$95
Apr 14, 2026	Wells Fargo	Yanan Zhu	PT Raise	Overweight	$50→$90
Apr 14, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$65→$80
Apr 14, 2026	Baird	Colleen Kusy	PT Raise	Outperform	$65→$90
Apr 14, 2026	Raymond James	Martin Auster	Initiate	Strong Buy	$80
Apr 14, 2026	Deutsche Bank	David Hoang	PT Raise	Buy	$55→$88

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Deutsche Bank Maintains Buy on Spyre Therapeutics, Lowers Price Target to $127

Deutsche Bank analyst David Hoang maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and lowers the price target from $135 to $127.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Spyre Therapeutics, Lowers Price Target to $123

Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and lowers the price target from $130 to $123.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on Spyre Therapeutics, Lowers Price Target to $121

BTIG analyst Julian Harrison maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and lowers the price target from $132 to $121.

Benzinga Newsdesk

Target To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Tuesday

Wall Street analysts changed outlook on top names. See complete view of all changes, upgrades, downgrades on analyst ratings page.

Avi Kapoor

PRO
BTIG Maintains Buy on Spyre Therapeutics, Raises Price Target to $132

BTIG analyst Julian Harrison maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the price target from $112 to $132.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Spyre Therapeutics, Raises Price Target to $115

Wells Fargo analyst Yanan Zhu maintains Spyre Therapeutics (NASDAQ:SYRE) with a Overweight and raises the price target from $90 to $115.

Benzinga Newsdesk